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INTRODUCTION
Retinopathy of prematurity (ROP) is a major avoidable cause of blindness in children. 1 In developed countries such as the USA, it is the second most common cause of childhood blindness. 2 Gilbert et al 3 suggest that heavier and more mature infants are developing severe ROP in countries with low or moderate levels of development compared with developed countries. ROP is emerging as an important cause of childhood blindness in developing countries because of significant improvement in survival rates of premature and low birthweight infants. However, there is a lack of awareness of the disease process and its screening criteria, compounded by a lack of skilled human resources to care for babies at risk of ROP. 4 Research from several developing countries, including India and China, has shown that the international screening criteria for ROP-gestational age ≤32 weeks and/or birth weight ≤1500 g-might not be entirely applicable in this developing part of the world. 5 6 Babies as heavy as 2000 g at birth and as mature as 35 weeks have been found to develop ROP. [6] [7] [8] Several investigators conclude that a significant proportion of ROP cases would have been missed had they used the recommended screening criteria, urging the need for development of regionspecific screening guidelines. 9 Hence, we decided to conduct a study to determine if broadening the criteria for ROP screening would have an impact on the number of babies diagnosed as having ROP.
METHODS
All infants-gestational age ≤35 weeks and birth weight ≤2000 g-born at the Aga Khan University Hospital (AKUH), Karachi, from May 2010 to December 2012 were screened for the presence of ROP. The study was approved by the Ethical Review Committee of Aga Khan University, Karachi. Informed consent was obtained from the parents. Data were collected prospectively on gestational age, birth weight, postnatal age, neonatal illnesses (eg, respiratory distress syndrome, sepsis and apnoea) and treatment received (eg, supplemental oxygen, phototherapy, blood transfusions and surfactant therapy).
All infants meeting the screening criteria were scheduled for their first examination between 4 and 6 weeks of life. Dilated fundus examinations were carried out in the clinic or neonatal intensive care unit (NICU) under topical anaesthesia by the consultant ophthalmologist (TAC). Tropicamide (0.5%) and phenylephrine (2.5%) eye drops were administered three times, 15 min apart, before each examination. Binocular indirect ophthalmoscopy was performed using a 20D and 30D lens. Lid speculum and scleral depressors were used to ensure adequate examination.
The 'International Classification of ROP' guidelines were used to record stage of the disease, location by zone, signs of plus disease and signs of regression. 10 Babies with no ROP were examined at 2-weekly intervals until they reached 40 weeks post-conception age. Babies with stage 1 and 2 disease were followed up weekly to see if disease regressed or if it progressed to stage 3, in which case treatment was then offered. Infants with stage 3 ROP were treated with argon laser, with or without intravitreal injections of bevacizumab, within 72 h of diagnosis and followed weekly.
The termination of acute retinal screening examinations was based on the latest guidelines by the American Academy of Pediatrics (AAP), American Academy of Ophthalmology and American Association for Pediatric Ophthalmology and Strabismus. 5 All data was analysed using IBM SPSS Statistics (V.19, SPSS Inc., an IBM company, Armonk, New York, USA). Data for gestational age and birth weight for those who did and did not develop ROP were expressed in the form of mean±SD values. Proportions were calculated for categorical variables. The presence of risk factors among those with and without ROP were tested for statistical significance using the χ 2 test or univariate binary logistic regression. Independent variables that were associated with ROP with p≤0.2 were included in the multivariate binary logistic regression to identify the independent predictors of ROP. A p value < 0.05 was considered statistically significant.
RESULTS
From April 2010 to December 2012, a total of 424 babies born at the AKUH fulfilled the eligibility criteria and their parents were invited to allow their participation in the study. Of these, 30 died while in the neonatal intensive care unit and 93 patients did not attend the first scheduled appointment. A total of 301 babies were examined; 163 (54.2%) were boys. The mean (±SD) gestational age of study subjects was 31.2±2.3 weeks and the mean birth weight was 1505±427 g ( (table 3) . Of those with ROP, 18 (66.7%) had stage 3 and 1 had stage 4 disease. The mean number of examinations was 2.06±1.47. Overall 93.7% babies were examined until they reached 40 weeks post-conception age or were fully vascularised.
In the univariate analysis, factors significantly associated with ROP included birth weight, gestational age, supplemental oxygen, surfactant therapy, septicaemia, birth apnoea, blood transfusions and respiratory distress syndrome (table 4) . Except supplemental oxygen, all other predictors were included in the multivariate analysis, which showed only gestational age as an independent predictor of ROP (adjusted relative risk 0.774, 95% CI 0.603 to 0.994). All 19 babies with stage 3 ROP or worse were treated, of whom 16 received laser and intravitreal bevacizumab injection and 3 received laser treatment alone.
DISCUSSION
Contrary to the findings of several previous studies in lowincome countries, our study showed that none of the infants falling outside the current screening criteria used across the world (ie, gestational age ≤32 weeks and/or BW ≤1500 g) developed ROP.
Studies from India, China, Saudi Arabia and Turkey suggested that a significant proportion of babies requiring ROP treatment might have been missed had they used a narrower screening criterion. 6 9 11-13 In light of such data, we decided to broaden our screening criteria. However, of 66 infants (GA >32 weeks & BW >1500 g) in our study, none developed ROP. It remains unclear how many babies of this weight and age need to be screened to detect one additional case of ROP and whether these estimates would differ in different settings.
As part of our study, we also identified factors that could increase the risk of such babies for developing ROP. Gestational age emerged as independent risk factors for the development of ROP. It is also important to mention that determination of correct gestational age of a baby is also a significant challenge in developing countries especially among less educated. Incorrect measure of GA may have resulted in misclassification of risk in this study as well as other studies. The incidence of ROP in our study (11.5%) is much lower than that reported in several previous studies. A possible explanation for these variations, besides genetics, could be the relative distribution of extremely premature babies and distribution of ROP risk factors.
Threshold ROP (stage 3 or worse) was seen in 19 of the 27 babies (70.4%) who developed ROP. A study from India also reported threshold disease in 62/138 (45%) babies. 6 A limitation of our study was that it looked at ROP incidence in just one hospital at a major Pakistan University with good neonatal care. Things may be very different at smaller hospitals in the country where neonatal care is not as advanced. Future studies should include multiple high-volume centres to increase generalisability. Patient compliance with regular follow-up examinations was a limitation of our study. Reasons for low compliance likely include lack of understanding of the seriousness of ROP as well as the financial constraints of the patients' families. Lack of appropriate counselling of parents by paediatricians/ neonatologists regarding the need for ophthalmic examination in at-risk infants continues to be a factor for failure to have their babies screened. Thus, we continue to see cases where patients seek medical care only when the disease has reached an irreversible stage with loss of red reflex and permanent loss of vision.
Our current screening criteria adopted from the guidelines set by the AAP, the American Association for Pediatric Ophthalmology and Strabismus, and the American Academy of Ophthalmology appear appropriate for the clinical setting of ROP screening in Pakistan. However, a larger multicentre study is needed to determine how many babies above this criterion need to be screened to detect one additional case of ROP and how cost effective such a programme will be.
